Literature DB >> 6695354

Amiodarone pneumonitis: three further cases with a review of published reports.

J I Darmanata, N van Zandwijk, D R Düren, E A van Royen, W J Mooi, T A Plomp, H M Jansen, D Durrer.   

Abstract

Three further patients are presented who developed evidence of a parenchymal pulmonary disturbance in the course of treatment with amiodarone. In one case the progress of the condition was rapid and ended fatally. Histological examination of the lungs showed evidence of diffuse alveolar damage. The concentration of amiodarone was from four to seven times higher in the lungs than in other organs studied. The concentration of the metabolite desethylamiodarone in the lungs was even higher in relation to other organs studied. The remaining two patients showed a more insidious onset and improvement after withdrawal of amiodarone and treatment with corticosteroids. Gallium 67 scintigraphy appeared to be a sensitive indicator of this adverse effect. Review of published reports revealed 35 cases of amiodarone pneumonitis, including the cases reported in this study. In 11 instances the dose of amiodarone was 400 mg or less. The onset was either insidious or rapidly progressive. Exertional dyspnoea was always present and a nonproductive cough, hypoxaemia, a raised erythrocyte sedimentation rate and diminished carbon monoxide diffusing capacity (transfer factor) were usually noted. Chest radiographs showed either a reticular pattern or diffuse patchy alveolar infiltrates. Discontinuation of amiodarone and an institution of corticosteroid treatment was usually followed by improvement or resolution.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6695354      PMCID: PMC459722          DOI: 10.1136/thx.39.1.57

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  27 in total

1.  Alveolitis after treatment with amiodarone.

Authors:  S A Riley; S E Williams; N J Cooke
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-16

2.  Pulmonary infiltration and bone marrow depression complicating treatment with amiodarone.

Authors:  A J Wright; R G Brackenridge
Journal:  Br Med J (Clin Res Ed)       Date:  1982-05-01

3.  Pulmonary bronchiolar alkylation and necrosis by 3-methylfuran, a naturally occurring potential atmospheric contaminant.

Authors:  M R Boyd; C N Statham; R B Franklin; J R Mitchell
Journal:  Nature       Date:  1978-03-16       Impact factor: 49.962

4.  67Ga scintigraphy as an index of disease activity in pulmonary sarcoidosis.

Authors:  C Alberts; J B van der Schoot; A S Groen
Journal:  Eur J Nucl Med       Date:  1981

5.  Possible association of pneumonitis with amiodarone therapy.

Authors:  H H Rotmensch; M Liron; M Tupilski; S Laniado
Journal:  Am Heart J       Date:  1980-09       Impact factor: 4.749

6.  Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug.

Authors:  S M Sobol; L Rakita
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

7.  Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients.

Authors:  H L Waxman; W C Groh; F E Marchlinski; A E Buxton; L M Sadowski; L N Horowitz; M E Josephson; J A Kastor
Journal:  Am J Cardiol       Date:  1982-11       Impact factor: 2.778

8.  In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol.

Authors:  M R Boyd; L T Burka
Journal:  J Pharmacol Exp Ther       Date:  1978-12       Impact factor: 4.030

9.  Amiodarone pulmonary toxicity.

Authors:  F E Marchlinski; T S Gansler; H L Waxman; M E Josephson
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

10.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Jackman; G V Naccarelli; K A Warfel; R L Rinkenberger; D P Zipes
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

View more
  7 in total

1.  Segmental pulmonary consolidation due to amiodarone.

Authors:  P Gibb; L J Melendez
Journal:  CMAJ       Date:  1986-03-15       Impact factor: 8.262

2.  Amiodarone pulmonary toxicity: functional and ultrastructural evaluation.

Authors:  F L Liu; R D Cohen; E Downar; J W Butany; J D Edelson; A S Rebuck
Journal:  Thorax       Date:  1986-02       Impact factor: 9.139

Review 3.  Amiodarone: review of pulmonary effects and toxicity.

Authors:  Spyros A Papiris; Christina Triantafillidou; Likurgos Kolilekas; Despoina Markoulaki; Effrosyni D Manali
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

4.  Prehospital amiodarone may increase the incidence of acute respiratory distress syndrome among patients at risk.

Authors:  Lioudmila V Karnatovskaia; Emir Festic; Ognjen Gajic; Rickey E Carter; Augustine S Lee
Journal:  J Crit Care       Date:  2012-01-04       Impact factor: 3.425

5.  Pulmonary complications after long term amiodarone treatment.

Authors:  J Roca; M Heras; R Rodriguez-Roisin; J Magriñà; A Xaubet; G Sanz
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

6.  Amiodarone-induced pulmonary toxicity mimicking metastatic lung disease.

Authors:  P Patel; D Honeybourne; R D Watson
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

7.  Amiodarone-induced loculated pleural effusion without pulmonary parenchymal involvement: A case report and literature review.

Authors:  Amer Hawatmeh; Mohammad Thawabi; Ashraf Jmeian; Hamid Shaaban; Fayez Shamoon
Journal:  J Nat Sci Biol Med       Date:  2017 Jan-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.